Abstract:
The invention concerns a compound of formula (I), wherein: (a) represents a single or double bond; (b) represents a cycle selected among (i), (ii), (iii), (iv) and (v); R9a, R9b, R9c, X and Y are such as defined in the description; R1 represents a group selected among hydrogen, aryl, heteroaryl, cycloalkyl, alkyl optionally substituted, and COR11, wherein R11 is such as defined in the description; R2 to R8 represent each a group selected among hydrogen, halogen, hydroxy, polyhalogenoalkyl, nitro, alkyl optionally substituted, amino optionally substituted, alkoxy optionally substituted, -OPO(OH)2 and (II), wherein m represents an integer such that 1
Abstract translation:本发明涉及式(I)化合物,其中:(a)表示单键或双键; (b)表示选自(i),(ii),(iii),(iv)和(v)中的循环; R9a,R9b,R9c,X和Y如描述中所定义; R 1表示选自氢,芳基,杂芳基,环烷基,任选取代的烷基和COR 11中的基团,其中R 11如说明书中所定义; R 2至R 8表示选自氢,卤素,羟基,多卤代烷基,硝基,任选取代的烷基,任选取代的氨基,任选取代的烷氧基,-OPO(OH)2和(II)中的基团,其中m表示1 R 3或具有R 4的R 3或具有R 5的R 4一起与含有任选含有1或2个杂原子并任选取代的单环或双环基团的碳原子一起形成; R 16表示氢原子或烷基; (c)表示芳基,杂芳基或芳基烷基; 以及其光学异构体,其与药学上可接受的酸或碱的加成盐以及其水合物和溶剂合物。 本发明可用于制备药物。
Abstract:
An extended-release composition of trimetazidine, wherein the internal phase comprises trimetazidine and the outer layer comprises a retardant and an anti-caking agent.
Abstract:
Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer.
Abstract:
Compounds of formula (I) in which: A is a (hetero)aromatic or non-(hetero)aromatic ring containing 5, 6 or 7 ring members, Z1, Z2 and Z3 are, independently of one another, a CH group or a nitrogen atom, with at least one of these three groups being a nitrogen atom, X is an alkylene chain as defined in the description, R2 is an aryl or heteroaryl group, and the R1 group is a group of formula (II) as defined in the description.
Abstract:
The invention relates to compounds of the formula (I) in which A is an angiotensine-converting enzyme inhibitor including at least one salifiable basic function, B is a compound including at least one acidic sailifiable function and at least one NO-donor group, m is the number of acidic salified functions of B, and n is the number of basic salified functions of A, provided that the bond(s) between A and B are of the ionic type. The invention can be used in drugs.
Abstract:
Compounds of formula (I): in which: R1 is an alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, and X is an N-OR2 group in which R2 is a hydrogen atom or an alkyl group. Medicaments.
Abstract:
The crystalline form III of a compound of formula (I) is characterised by the X diffraction diagram thereof on a powder. Can be used for drugs
Abstract:
The invention relates to sinomenine and compounds thereof and also to compounds of formula (I), wherein R1 represents an alkyl group; R2 represents a hydrogen atom or an alkylcarbonyl group, an haloalkylcarbonyl group or an arylcarbonyl; Y represents a group (II), (III) or (IV); R3 ,R4, R'4, R5, R'5 and R6 are as defined in the description; and X represents a halogen atom. Medicaments.